Mota, Alba
Oltra, Sara S.
Selenica, Pier
Moiola, Cristian P.
Casas-Arozamena, Carlos http://orcid.org/0000-0002-3279-2482
López-Gil, Carlos
Diaz, Eva
Gatius, Sonia
Ruiz-Miro, María
Calvo, Ana
Rojo-Sebastián, Alejandro
Hurtado, Pablo
Piñeiro, Roberto http://orcid.org/0000-0001-9479-139X
Colas, Eva
Gil-Moreno, Antonio http://orcid.org/0000-0003-1106-5590
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Muinelo-Romay, Laura
Abal, Miguel http://orcid.org/0000-0003-3533-7781
Matias-Guiu, Xavier
Weigelt, Britta
Moreno-Bueno, Gema http://orcid.org/0000-0002-5030-6687
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CIBERONC, CB16/12/00295)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30CA008748)
Article History
Received: 27 May 2021
Revised: 12 January 2022
Accepted: 27 January 2022
First Online: 10 February 2022
Competing interests
: JSR-F reports receiving personal/consultancy fees from Goldman Sachs, REPARE Therapeutics, Paige.AI and Eli Lilly, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Paige.AI, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech and InVicro, outside the scope of this study. BW reports ad hoc membership of the scientific advisory board of REPARE Therapeutics, outside the scope of this study. The remaining authors have no conflict of interests to declare.